• Je něco špatně v tomto záznamu ?

Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study

CFJ. Antonides, F. Schoenrath, TMMH. de By, R. Muslem, K. Veen, YC. Yalcin, I. Netuka, J. Gummert, EV. Potapov, B. Meyns, M. Özbaran, D. Schibilsky, K. Caliskan, EUROMACS investigators

. 2020 ; 7 (3) : 1085-1094. [pub] 20200320

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020478

Grantová podpora
European Association for Cardio-Thoracic Surgery - International

AIMS: Sufficient myocardial recovery with the subsequent explantation of a left ventricular assist device (LVAD) occurs in approximately 1-2% of the cases. However, follow-up data about this condition are scarcely available in the literature. This study aimed to report the long-term outcomes and clinical management following LVAD explantation. METHODS AND RESULTS: An analysis of the European Registry for Patients with Mechanical Circulatory Support was performed to identify all adult patients with myocardial recovery and successful explantation. Pre-implant characteristics were retrieved and compared with the non-recovery patients. The follow-up data after explantation were collected via a questionnaire. A Kaplan-Meier analysis for freedom of the composite endpoint of death, heart transplantation, LVAD reimplantion, or heart failure (HF) relapse was conducted. A total of 45 (1.4%) cases with myocardial recovery resulting in successful LVAD explantation were identified. Compared with those who did not experience myocardial recovery, the explanted patients were younger (44 vs. 56 years, P < 0.001), had a shorter duration of cardiac disease (P < 0.001), and were less likely to have ischaemic cardiomyopathy (9% vs. 41.8%, P < 0.001). Follow-up after explantation could be acquired in 28 (62%) cases. The median age at LVAD implantation was 43 years (inter-quartile range: 29-52), and 23 (82%) were male. Baseline left ventricular ejection fraction was 18% (inter-quartile range: 10-20%), and 60.7% of the patients had Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 or 2. Aetiologies of HF were dilated cardiomyopathy in 36%, myocarditis in 32%, and ischaemic in 14% of the patients, and 18% had miscellaneous aetiologies. The devices implanted were HeartMate II in 14 (50%), HVAD in 11 (39%), HeartMate 3 in 2 (7%), and 1 unknown with a median duration of support of 410 days (range: 59-1286). The median follow-up after explantation was 26 months (range 0.3-73 months), and 82% of the patients were in New York Heart Association Class I or II. Beta-blockers were prescribed to 85%, angiotensin-converting enzyme inhibitors to 71%, and loop diuretics to 50% of the patients, respectively. Freedom from the composite endpoint was 100% after 30 days and 88% after 2 years. CONCLUSIONS: The survival after LVAD explantation is excellent without the need for heart transplantation or LVAD reimplantation. Only a minority of the patients suffer from a relapse of significant HF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020478
003      
CZ-PrNML
005      
20210830102137.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.12629 $2 doi
035    __
$a (PubMed)32196996
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Antonides, Christiaan F J $u Thoraxcenter, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands
245    10
$a Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study / $c CFJ. Antonides, F. Schoenrath, TMMH. de By, R. Muslem, K. Veen, YC. Yalcin, I. Netuka, J. Gummert, EV. Potapov, B. Meyns, M. Özbaran, D. Schibilsky, K. Caliskan, EUROMACS investigators
520    9_
$a AIMS: Sufficient myocardial recovery with the subsequent explantation of a left ventricular assist device (LVAD) occurs in approximately 1-2% of the cases. However, follow-up data about this condition are scarcely available in the literature. This study aimed to report the long-term outcomes and clinical management following LVAD explantation. METHODS AND RESULTS: An analysis of the European Registry for Patients with Mechanical Circulatory Support was performed to identify all adult patients with myocardial recovery and successful explantation. Pre-implant characteristics were retrieved and compared with the non-recovery patients. The follow-up data after explantation were collected via a questionnaire. A Kaplan-Meier analysis for freedom of the composite endpoint of death, heart transplantation, LVAD reimplantion, or heart failure (HF) relapse was conducted. A total of 45 (1.4%) cases with myocardial recovery resulting in successful LVAD explantation were identified. Compared with those who did not experience myocardial recovery, the explanted patients were younger (44 vs. 56 years, P < 0.001), had a shorter duration of cardiac disease (P < 0.001), and were less likely to have ischaemic cardiomyopathy (9% vs. 41.8%, P < 0.001). Follow-up after explantation could be acquired in 28 (62%) cases. The median age at LVAD implantation was 43 years (inter-quartile range: 29-52), and 23 (82%) were male. Baseline left ventricular ejection fraction was 18% (inter-quartile range: 10-20%), and 60.7% of the patients had Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 or 2. Aetiologies of HF were dilated cardiomyopathy in 36%, myocarditis in 32%, and ischaemic in 14% of the patients, and 18% had miscellaneous aetiologies. The devices implanted were HeartMate II in 14 (50%), HVAD in 11 (39%), HeartMate 3 in 2 (7%), and 1 unknown with a median duration of support of 410 days (range: 59-1286). The median follow-up after explantation was 26 months (range 0.3-73 months), and 82% of the patients were in New York Heart Association Class I or II. Beta-blockers were prescribed to 85%, angiotensin-converting enzyme inhibitors to 71%, and loop diuretics to 50% of the patients, respectively. Freedom from the composite endpoint was 100% after 30 days and 88% after 2 years. CONCLUSIONS: The survival after LVAD explantation is excellent without the need for heart transplantation or LVAD reimplantation. Only a minority of the patients suffer from a relapse of significant HF.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    12
$a srdeční selhání $x chirurgie $7 D006333
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a tepový objem $7 D013318
650    _2
$a výsledek terapie $7 D016896
650    _2
$a funkce levé komory srdeční $7 D016277
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schoenrath, Felix $u Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, Berlin, Germany $u DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
700    1_
$a de By, Theo M M H $u Thoraxcenter, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands $u EUROMACS, EACTS, Windsor, UK
700    1_
$a Muslem, Rahatullah $u Thoraxcenter, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands
700    1_
$a Veen, Kevin $u Thoraxcenter, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands
700    1_
$a Yalcin, Yunus C $u Thoraxcenter, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands $u Thoraxcenter, Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands
700    1_
$a Netuka, Ivan $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Gummert, Jan $u Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Centre, NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
700    1_
$a Potapov, Evgenij V $u Department of Cardiothoracic and Vascular Surgery, German Heart Centre Berlin, Berlin, Germany $u DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
700    1_
$a Meyns, Bart $u Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Özbaran, Mustafa $u Department of Cardiovascular Surgery, Ege Üniversitesi Tıp Fakültesi, Izmir, Turkey
700    1_
$a Schibilsky, David $u Department of Cardiovascular Surgery, Universitäts-Herzzentrum Freiburg-Bad Krozingen, Freiburg, Germany
700    1_
$a Caliskan, Kadir $u Thoraxcenter, Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands
710    2_
$a EUROMACS investigators
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 7, č. 3 (2020), s. 1085-1094
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32196996 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102138 $b ABA008
999    __
$a ok $b bmc $g 1691113 $s 1140924
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 7 $c 3 $d 1085-1094 $e 20200320 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
GRA    __
$p European Association for Cardio-Thoracic Surgery $2 International
LZP    __
$a Pubmed-20210728
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace